Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Quan Capital Closes Second Healthcare Fund at $275 Million

publication date: Sep 4, 2019

Quan Capital, a Shanghai healthcare venture firm, closed its second fund with $275 million in commitments, according to media reports. In 2018, Quan announced it would begin fundraising for second fund with a $300 million target, one year after it closed its $150 million initial fund. Quan is very closely allied with Zai Lab. Samantha Du, PhD, heads both companies and other members of Zai's senior management are also part of Quan's team. Quan seeks venture and growth investments in disruptive companies globally and in China. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.